Assessing the relationship of patient global assessment of disease activity and health related quality of life by SF-36 with other patient-reported outcomes in rheumatoid arthritis: post hoc analyses of data from phase 3 trials of baricitinib
Main Authors: | Strand, V, Sebba, A, Scardo, S, Quebe, A, Zaremba-Pechmann, L, Taylor, P, Sholter, D |
---|---|
Format: | Conference item |
Language: | English |
Published: |
Journal of Rheumatology
2022
|
Similar Items
-
Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
by: Strand, V, et al.
Published: (2021) -
Baricitinib for the treatment of rheumatoid arthritis
by: Ivan Urits, et al.
Published: (2020-12-01) -
SF-36 questionnaire and its utilization in rheumatoid arthritis
by: Sh Erdes, et al.
Published: (2003-04-01) -
Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
by: Fautrel, B, et al.
Published: (2017) -
Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
by: Taylor, P, et al.
Published: (2019)